Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3170918 | 1.00 | DRD2 (0.43) | DRD2DRD1NPC1RAB9ACTSD | |
| SCHEMBL8307806 | 0.90 | DRD2 (0.48) | DRD2DRD1NPC1RAB9ACTSD | |
| SCHEMBL20841104 | 0.87 | OPRD1 (0.47) | DRD2DRD1NPC1RAB9AUGT2B17 | |
| SCHEMBL1346504 | 0.83 | BACE1 (0.39) | DRD2BACE1UGT2B17CHRM4HTR7 | |
| SCHEMBL23789054 | 0.83 | UGT2B17 (0.37) | DRD2UGT2B17CHRM4HTR7ESR1 | |
| SCHEMBL5713886 | 0.81 | DRD2 (0.41) | DRD2DRD1NPC1RAB9ACTSD | |
| SCHEMBL6330755 | 0.80 | ACHE (0.50) | DRD2DRD1NPC1RAB9ACTSD | |
| SCHEMBL8281689 | 0.80 | ACHE (0.50) | DRD2DRD1NPC1RAB9ACTSD | |
| Hydrochloric Acid SCHEMBL3171185 | 0.79 | ACHE (0.49) | DRD2DRD1CTSDBACE1CYP2D6 | |
| SCHEMBL8312130 | 0.78 | CTSD (0.47) | DRD2DRD1NPC1RAB9ACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | ARS Pharmaceuticals, Inc. | 2020-01-30 | — | — | US | disclosed |
| US-10442790-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-9090619-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140343315-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| US-20140155431-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130011923-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | US | disclosed |
| US-8242149-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080207696-A1 | Phenacyl 2-Hydroxy-3-Diaminoalkanes | AQUINO JOSE | 2008-08-28 | — | — | US | disclosed |
| CN-100384824-C | Acetyl 2-hydroxy-1, 3-diaminoalkanes | PHARMACIA & UPJOHN CO LLC (US) | 2008-04-30 | — | — | CN | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-15 | — | — | US | disclosed |
| CN-1694870-A | Acetyl 2-hydroxy-1, 3-diaminoalkanes | PHARMACIA & UPJOHN CO LLC (US) | 2005-11-09 | — | — | CN | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2004094413-A1 | PHENACYL 2-HYDROXY-3-DIAMINOALKANES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343315-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | DRD2 4680/4885DRD1 4761/4885NPC1 28/4885 |
| US-20140155431-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | DRD2 4680/4885DRD1 4761/4885NPC1 28/4885 |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | BACE1, BACE2, APP | DRD2 2640/4885DRD1 2102/4885NPC1 1553/4885 |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | DRD2 4668/4885DRD1 4760/4885NPC1 29/4885 |
| US-10442790-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | DRD2 327/4885DRD1 866/4885NPC1 1453/4885 |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | DRD2 4885/4885DRD1 4863/4885NPC1 1393/4885 |
| US-20080207696-A1 | Phenacyl 2-Hydroxy-3-Diaminoalkanes | APP, PSEN1, BACE2 | DRD2 4127/4885DRD1 4016/4885NPC1 1874/4885 |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | DRD2 327/4885DRD1 866/4885NPC1 1453/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | DRD2 2483/4885DRD1 2531/4885NPC1 1977/4885 |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | DRD2 2640/4885DRD1 2102/4885NPC1 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.